Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3912]

Isatuximab + Kd in RRMM: Depth of Response Results From the IKEMA Trial

Dr Maximilian Merz - Leipzig University, Leipzig, Germany

Isatuximab + Kd in RRMM: Depth of Response Results From the IKEMA Trial ( Dr Maximilian Merz - Leipzig University, Leipzig, Germany )

Cancer patient symptom and physical function reporting by caregivers used as...

Dr Elad Neeman - Kaiser Permanente San Francisco Medical Center, San Francisco...

Cancer patient symptom and physical function reporting by caregivers used as predictors of adverse clinical outcomes ( Dr Elad Neeman - Kaiser Permanente San Francisco Medical Center, San Francisco, USA )

War in Ukraine: Global cancer aid to support refugees

Dr Horia Vulpe , Dr Ruslan Baltaga

War in Ukraine: Global cancer aid to support refugees ( Dr Horia Vulpe , Dr Ruslan Baltaga )

War in Ukraine: The International Brain Tumour Alliance's response to aiding...

Kathy Oliver - Chair and Co-Director, International Brain Tumour Alliance

War in Ukraine: The International Brain Tumour Alliance's response to aiding refugees during the crisis ( Kathy Oliver - Chair and Co-Director, International Brain Tumour Alliance )

Rucaparib effective as maintenance therapy following first-line platinum-based...

Dr Bradley Monk - University of Arizona College, Tucson, USA

Rucaparib effective as maintenance therapy following first-line platinum-based chemo in ovarian cancer ( Dr Bradley Monk - University of Arizona College, Tucson, USA )

RAGNAR study evidences efficacy and safety of erdafitinib in patients with...

Dr Yohann Loriot - Institut Gustave Roussy, Villejuif, France

RAGNAR study evidences efficacy and safety of erdafitinib in patients with advanced FGFR+ malignancies ( Dr Yohann Loriot - Institut Gustave Roussy, Villejuif, France )

ASCO 2022: The latest in mRCC

Prof James Larkin, Dr Bernard Escudier, Prof Jens Bedke and Dr Toni Choueiri

ASCO 2022: The latest in mRCC ( Prof James Larkin, Dr Bernard Escudier, Prof Jens Bedke and Dr Toni Choueiri )

ASCO and WHO to collaborate on quality indicators for cancer facilities

Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland

ASCO and WHO to collaborate on quality indicators for cancer facilities ( Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland )

CAR-T cell therapy targeting BCMA is highly effective for patients with...

Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain

$CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma ( Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain )$

Treatment with high-dose multi-agent chemotherapy for high-risk lymphoma is...

Dr Martine Chamuleau - Amsterdam UMC, Amsterdam, Netherlands

Treatment with high-dose multi-agent chemotherapy for high-risk lymphoma is effective but with significant toxicity ( Dr Martine Chamuleau - Amsterdam UMC, Amsterdam, Netherlands )

Comment: Addition of ixazomib to pomalidomide and dexamethasone improves...

Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA

Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )

EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for...

Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA

EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )

More from ecancer